Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.

Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG; National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group..

BMJ. 2009 Jul 14;339:b2538. doi: 10.1136/bmj.b2538.

3.

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.

Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, Rostom A, Symmons D.

Health Technol Assess. 2006 Oct;10(38):iii-iv, xi-xiii, 1-183. Review.

4.

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.

Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D.

Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. Review.

5.
6.
7.

Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.

Scheiman JM, Hindley CE.

Clin Ther. 2010 Apr;32(4):667-77. doi: 10.1016/j.clinthera.2010.04.009. Review.

PMID:
20435236
9.

Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.

Chaiamnuay S, Allison JJ, Curtis JR.

Am J Health Syst Pharm. 2006 Oct 1;63(19):1837-51. Review.

PMID:
16990630
10.

The use of NSAIDs in rheumatic disorders 2005: a global perspective.

Kean WF, Buchanan WW.

Inflammopharmacology. 2005;13(4):343-70. Review.

PMID:
16354389
11.

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

Spiegel BM, Targownik L, Dulai GS, Gralnek IM.

Ann Intern Med. 2003 May 20;138(10):795-806. Review.

PMID:
12755551
12.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

13.
14.
15.
16.

[Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].

van den Bemt BJ, Benraad HB, Rasker JJ.

Ned Tijdschr Geneeskd. 2007 May 12;151(19):1062-7. Review. Dutch.

PMID:
17552414
17.
18.
20.

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.

Moore RA, Derry S, Makinson GT, McQuay HJ.

Arthritis Res Ther. 2005;7(3):R644-65. Review. Erratum in: Arthritis Res Ther. 2006;8(1):401.

Items per page

Supplemental Content

Support Center